Postmenopausal hormone replacement therapy and cardiovascular disease: The value of transdermal estradiol and micronized progesterone

Climacteric

Volumn 15, Issue SUPPL.1, 2012, Pages 11-17

  Mueck, A O ^a  

^a University Women's Hospital   (Germany)

Author keywords

CARDIOVASCULAR DISEASE; HORMONE REPLACEMENT THERAPY; MYOCARDIAL INFARCTION; PROGESTERONE; STROKE; TRANSDERMAL ESTRADIOL; VENOUS THROMBOEMBOLISM

Indexed keywords

ACTIVATED PROTEIN C; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; PLACEBO; PROGESTERONE;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE; VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PROGESTERONE;

EID: 84858773629     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.669624     Document Type: Article

References (49)

1. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol - progesterone be a safer postmenopausal HRT? A review. Maturitas 2008;60:185-201
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
3. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
4. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs progestogens. Climactric 2012;15(Suppl 1): 18-25
5. Mueck AO. Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance. Menopause 2010;17:1099-103
6. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-2
7. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
8. Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost 2010;8:1736-44
9. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6 (Pubitemid 37108215)
10. Hoøibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-20 (Pubitemid 34203511)
11. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebocontrolled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21 (Pubitemid 36713570)
12. Martínez C, Basurto L, Zárate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 2005;50:39-43 (Pubitemid 39601707)
13. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost 2001;86:550-6 (Pubitemid 32743265)
14. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22 (Pubitemid 24058953)
15. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7 (Pubitemid 24144355)
16. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8
17. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-6 (Pubitemid 29076142)
18. Canonico M, Alhenc-Gelas M, Plu-Bureau G, OliéV, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122-7
19. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THrombo- Embolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32 (Pubitemid 36999704)
20. Canonico M, Fournier A, Carcaillon L, e t al . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5
21. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a populationbased study. J Thromb Haemost 2010;8:979-86
22. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31 (Pubitemid 351809317)
23. Straczek C, Oger E, Yon de Jonage-Canonico MB, e t al . Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500 (Pubitemid 43739566)
24. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006;4:1259-65
25. Oli éV, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011;18:488-93
26. Canonico M, Oger E, Plu-Bureau G, e t al . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5 (Pubitemid 46294724)
27. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11 (Pubitemid 29266405)
28. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:217-21 (Pubitemid 27057346)
29. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7
30. H ermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med 2008;5:387-95 (Pubitemid 351935572)
31. Simoncini T, Caruso A, Giretti MS, et al. Effects of dydrogesterone and of its stable metabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006;86(Suppl):1235-42 (Pubitemid 44427819)
32. Loøkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Oø . Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-8
33. Gruppetta M, Calleja N, Fava S. Long-term survival after acute myocardial infarction and relation to type 2 diabetes and other risk factors. Clin Cardiol 2010;33:424-9
34. Bouhanick B, Cambou JP, Ferriè res J, Amelineau E, Guize L. Characteristics and six-month outcomes in a cohort of 8288 diabetic and non-diabetic patients with previous history of acute coronary syndrome or stroke: the French PREVENIR 3 survey. Diabetes Metab 2006;32:460-6 (Pubitemid 44836588)
35. Ovbiagele B, Markovic D, Fonarow GC. Recent US patterns and predictors of prevalent diabetes among acute myocardial infarction patients. Cardiol Res Pract 2011;2011:145615
36. de Lauzon-Guillain B, Fournier A, Fabre A, e t al . Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle G én érale de l'Education Nationale (E3N) cohort. Diabetologia 2009;52:2092-100
37. Lobo RA, Clarkson TB. Different mechanisms for benefi t and risk of coronary heart disease and stroke in early postmenopausal women: a hypothetical explanation. Menopause 2011;18:237-40
38. Heistad DD. Unstable coronary-artery plaques. N Engl J Med 2003;349:2285-7 (Pubitemid 37509734)
39. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005;308:1583-7 (Pubitemid 40807497)
40. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcifi cation . N Engl J Med 2007;356: 2591-602 (Pubitemid 46961004)
41. Sumino H, Ichikawa S, Ohyama Y, et a l. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular infl ammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005;96:148-53 (Pubitemid 40853961)
42. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
43. Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause 2002;9:273-81 (Pubitemid 34743452)
44. Honisett SY, Pang B, Stojanovska L, Sudhir K, Komesaroff PA. Progesterone does not infl uence vascular function in postmenopausal women. J Hypertens 2003;21:1145-9 (Pubitemid 36667868)
45. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208
46. Rylance PB, Brincat M, Lafferty K, e t al. Natural progesterone and antihypertensive action. Br Med J (Clin Res Ed) 1985;290: 13-14 (Pubitemid 15075974)
47. Lee DY, Kim JY, Kim JH, e t al . Effects of hormone therapy on ambulatory blood pressure in postmenopausal Korean women. Climacteric 2011;14:92-9
48. Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010;13:307-13
49. Simon JA. What' s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3-10.